ODAC Looks at Sample Audit to Lighten Load of PFS Trials
Forget whether progression-free survival (PFS) should be a surrogate endpoint in cancer trials, the FDA said as it charged the Oncologic Drug Advisory Committee (ODAC) Tuesday to look at reducing the central review audit burden as a way to streamline cancer trials.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter